Aydın, Emre E.Aydın, Fatma YılmazDemir, YakupYıldırım, YaşarÇelen, Mustafa Kemal2022-03-182022-03-182021Aydın, E. E., Aydın, F. Y., Demir, Y., Yıldırım, Y. ve Çelen, M. K. (2021). Evaluation of kidney function tests in HIV-positive patients receiving combined antiretroviral therapy. International Journal of Clinical Practice, 75(8), e14542.1368-5031https://onlinelibrary.wiley.com/doi/10.1111/ijcp.14542https://hdl.handle.net/11468/9456PMID: 34137140WOS:000667245000001Introduction: Human immunodeficiency virus is a chronic infection that attacks the immune system of the human body, particularly CD4 T lymphocytes. Combined antiretroviral therapies are highly effective in virological suppression of human immunodeficiency virus infection. It has been shown that some retroviral therapies have a higher nephrotoxicity potential. As a result of renal injury, serum creatinine increases and the estimated glomerular filtration rate is reduced. The aim of our study was to assess changes in kidney function during a 24-month period in HIV-positive patients who were begun on combined antiretroviral therapy. Material and Methods: A total of 127 HIV-positive patients were enrolled. The patients were divided into five groups; patients who received no therapy were designated as group 1; those who received Dolutegravir/Abacavir/Lamivudine combination as group 2; those who received Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate combination as group 3; those who received Emtricitabine/Tenofovir Disoproxil Fumarate/Dolutegravir combination as group 4; and those who received Emtricitabine/Tenofovir Disoproxil Fumarate/Raltegravir combination as group 5. We compared the effects of these drugs on estimated glomerular filtration rate during a 24-month follow-up period. Results: At the 24th month of therapy, a significant difference was observed between the estimated glomerular filtration rate (eGFR) levels of the study groups (P <.001). eGFR level was significantly higher in group 4 compared with groups 1, 2 and 3 (P =.009, P <.001, P <.001, respectively), whereas it was significantly lower in group 5 than groups 1, 2 and 3 (P =.005, P <.001, P [removed].05). Serum creatinine level was significantly higher in groups 4 and 5 compared with the other groups (P <.001). Conclusion: The use of TDF-containing regimens causes renal dysfunction. Therefore, we recommend close monitoring of renal function, especially in patients treated with TDF.eninfo:eu-repo/semantics/openAccessAdenineAnti-HIV AgentsEmtricitabineHIV InfectionsHIV-1HumansKidney Function TestsTenofovirArticle758e14542WOS:0006672450000012-s2.0-851108919743413714010.1111/ijcp.14542Q1Q2